TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) is now available.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announced changes to its Nomination Committee, appointing Ms. Fu Dawei and Dr. Kendall Arthur Smith as new members. These changes align with upcoming amendments to the Hong Kong Stock Exchange’s Listing Rules and Corporate Governance Code, aiming to enhance the company’s governance practices and board diversity.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in Shanghai, China. It operates in the healthcare industry, focusing on the development of innovative cancer immunotherapy treatments.
Average Trading Volume: 5,194,140
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.61B
Find detailed analytics on 1541 stock on TipRanks’ Stock Analysis page.